

**NOXXON TO ATTEND EUROPEAN INVESTOR AND PARTNERING CONFERENCES
IN NOVEMBER 2018**

Berlin, Germany, October 23, 2018, 6.00 p.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the company will attend the BIO-Europe Conference and the Salon Actionaria in November 2018.

NOXXON will attend BIO-Europe, one of the largest partnering conferences in Europe dedicated to life sciences, on Monday and Tuesday, November 5-6, 2018, held at the Bella Center in Copenhagen, Denmark. NOXXON will be available for meetings with investors during the conference.

NOXXON will also attend the Salon Actionaria, an event dedicated to individual shareholders and held at the Palais des Congrès in Paris, France, on November 22-23, 2018. Aram Mangasarian, Chief Executive Officer at NOXXON Pharma, will present an overview of the company as well as welcome visitors at the company stand.

For more information, please contact:

NOXXON Pharma N.V.

Aram Mangasarian, Ph.D., Chief Executive Officer
Tel. +49 (0) 30 726 247 0
amangasarian@noxxon.com

MC Services AG

Raimund Gabriel, Managing Partner
Tel. +49 (0) 89 210228 0
noxxon@mc-services.eu

Trophic Communications

Gretchen Schweitzer or Jacob Verghese
Tel. +49 (0) 89 2388 7730 or +49 (0) 173 364 1607
schweitzer@trophic.eu

NewCap

Alexia Faure
Tel. +33 (0) 1 44 71 98 51
afaure@newcap.fr

About NOXXON

NOXXON's oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor microenvironment, NOXXON's approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. The company plans to initiate further studies with NOX-A12 in brain cancer in combination with radiotherapy, for which an orphan drug status has been granted in the US and EU. The company's second asset, NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in pancreatic cancer patients both as a monotherapy and in combination. Further information can be found at: www.noxxon.com

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.



<https://www.linkedin.com/company/noxxon-pharma-ag>



https://twitter.com/noxxon_pharma

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.